Purified m-acrosin catalysed amidolysis of several p-nitroanilides with C-terminal arginine residues. Antithrombin III inhibited amidolysis catalysed by the enzyme. This effect of antithrombin III was potentiated by heparin, and to a modest extent by heparan sulphate, cellulose sulphate, dextran sulphate and xylan sulphate. De-Nsulphated heparin, de-N-sulphated N-acetylated heparin, heparin of low relative molecular mass, chondroitin 4-sulphate, chondroitin 6-sulphate, dermatan sulphate and hyaluronic acid were ineffective.
The plasma glycoprotein antithrombin III is probably the major mammalian physiological inhibitor of thrombin (EC 3.4 .21.5), of factor Xa (EC 3.4.21.6 ) and perhaps of some other serine proteinases catalysing reactions of the intrinsic coagulation cascade (Barrowcliffe & Thomas, 1981) . The inhibitor has been shown to be effective towards a few other proteinases in vitro. These include plasma kallikrein (EC 3.4.21.8; Rosenberg, 1977) , plasmin (EC 3.4.21.7; Rosenberg, 1977) , urokinase (formerly EC 3.4.99.26; Watson et al., 1981) , a proteinase released from mouse macrophages (Seljelid et al., 1980 ) and a cellsurface neutral proteinase from human leucocytes (Long et al., 1982) . In addition, proteinase inhibitors immunologically related to antithrombin III have been detected on guinea-pig T-lymphocyte membranes (Clement et al., 1981) and in numerous normal and malignant tissues (Twining & Brecher, 1977) .
Heparins, by a mechanism that is yet to be elucidated, accelerate the inhibitory action of antithrombin III towards at least some of the proteinases mentioned above; this effect forms the basis of the efficacy of heparins as clinical anticoagulants (Barrowcliffe & Thomas, 1981) . With the possible exception of heparans, which are structurally related to heparins, other purified glycosaminoglycans do not modulate antithrombin III activity (e.g. Kindness et al., 1980b ). Also, with the possible exceptions of CTs-inhibitor (Caughman et al., 1982) , and of partially characterized inhibitors named 'protease-nexin' (Baker et al., 1980) , ' antithrombin BM' (Wunderwald et al., 1982) and 'heparin cofactor II' (Tollefsen et al., 1982) , proteinase inhibitors other than antithrombin III are not potentiated by heparins.
Vascular-wall heparans may act as immobilized anticoagulants by potentiating the action of plasma or vascular-wall antithrombin III in a heparinlike manner (for discussion, see Long & Williamson, 1983a) , and it has been suggested that pericellular heparans in tissues other than blood vessels may also affect pericellular proteinase activities by potentiating the action of proteinase inhibitors similar to, or perhaps identical with, plasma antithrombin III (Long & Williamson, 1983a (Long & Williamson, 1983b) were prepared and characterized as previously described. Dermatan sulphate from porcine skin was supplied by Seikagaku Fine Biochemicals, Tokyo, Japan (lot no. S 9401). Enzymic and electrophoretic analysis of the preparation showed it to contain less than 0.2% (w/w) heparin (Long et al., 1980) . River S-2222 
nitroanilide hydrochloride and its methyl ester), S-2238 
were from KabiVitrum. Polybrene (NNNN-tetramethylhexane-1,6-diamine polymer with 1,3-dibromopropane) was from Sigma Chemical Co. m -Acrosin (specific activity approx. 130units/ mg ofE protein) purified from ovine spermatozoa (Harrison, 1982) (Teien et al., 1976) . Concentrations quoted are final concentrations in the reaction mixture after addition of substrate and Polybrene.
Results
In the assay system described, mp-acrosin in the absence of antithrombin III or polysaccharides catalysed the release of p-nitroaniline from pnitroanilides containing C-terminal arginine residues at the following initial reaction rates (AA'cm l*-l*min-') (all x 10-3): substrates S-2288, 5.8; S-2222, 4.0; S-2266, 3.9; S-2238, 3.5; S-2302, 2.7; S-2444, 2.3. Amidolysis of substrate S-2251, a p-nitroanilide containing a C-terminal lysine residue, was catalysed at a rate of 400 AA I 8c l -l min-.
Incubation of antithrombin III with enzyme before addition of substrate inhibited enzyme activity (Table 1) . No amidolysis was observed when antithrombin III was incubated with substrate in the absence of enzyme.
Incubation of heparin with antithrombin III before enzyme addition potentiated the action of antithrombin III; preincubation of Polybrene (0. 12mg/ml) with heparin before antithrombin III addition prevented this action of heparin (Fig. la) . No amidolysis was observed when, in the absence of enzyme, Polybrene, by itself or together with heparin or antithrombin III, was incubated with substrate. Also, Polybrene did not affect the (Figs. lb-lh) . In contrast, modest potentiation of antithrombin III action was observed at high concentrations of heparan sulphate, cellulose sulphate, dextran sul- (a) (b)
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.b Reaction rates are shown as percentages of control rates, i.e. the rates observed when mp-acrosin was, under the conditions specified, incubated with substrate and Polybrene only. Representative absolute reaction rates are quoted at the start of the Results section. Incubation of mp-acrosin, under the conditions specified, with antithrombin III, substrate and Polybrene and in the absence of polysaccharides, decreased the initial reaction rate to 98% of the control rate. Kindness et al., 1979a Kindness et al., , 1980c .
We have not demonstrated the mechanism by which heparin modulation of the antithrombin III inhibition of mfl-acrosin occurs. However, its prevention by Polybrene, and the ineffectiveness of the chemically modified and of the low-Mr heparin preparations resemble similar effects seen when heparin-modulated antithrombin III inhibition of other serine proteinases is examined (Teien et al., 1976; Long & Williamson, 1983b; Long et al., 1983) . The ineffectiveness of other glycosaminoglycans in potentiating antithrombin III action towards mp-acrosin resembles their ineffectiveness in potentiating antithrombin III action towards other serine proteinases (Kindness et al., 1979a (Kindness et al., , 1980c Watson et al., 1981) . The modest effect of the heparan sulphate, seen here and elsewhere in other antithrombin III-serineproteinase systems (Teien et al., 1976; Kindness et al., 1979a Kindness et al., , 1980c Watson et al., 1981) (Kindness et al., 1979b (Kindness et al., ,c, 1980a Watson et al., 1981) .
Acrosin, largely in zymogen form, is present within the acrosome, an intracellular spermatazoon organelle. Prevention of fertilization in vitro and in vivo by acrosin inhibitors suggests the importance of acrosin during fertilization, possibly in enabling spermatazoon penetration of the zona pellucida of the ovum and/or in participation in the acrosome reaction, a series of events leading to release or exposure of acrosomal contents. These considerations have stimulated interest in the effectiveness of proteinase inhibitors on acrosin activity, and in their possible function as physiological modulators of acrosin activity and possible use as pharmacological contraceptives (Hartree, 1977; Morton, 1977) . Sulphated glycosaminoglycans are synthesized in ovarian tissue (Clinton et al., 1983) ; in vitro, some may affect the acrosome reaction (Lenz et al., 1982) and the production of acrosin from its zymogen (Wincek et al., 1979; Parrish et al., 1980) . The possibility of endogenous or exogenous sulphated polysaccharide modulation of antithrombin III or antithrombin III-like effects on spermatozoal proteinases in vivo should be considered.
